What is CUSIP 15117K103?

CUSIP 15117K103 is the security identifier used in SEC filing datasets for CLLS - Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share.

Security Snapshot

Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS) Institutional Ownership

Q: Who owns CLLS - Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share based on 13F filings?

27 institutions reported positions in CLLS - Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share as of Q2 2026. Open the latest holders period and ownership history tables on this page for position-level details.

CUSIP: 15117K103

13F Institutional Holders and Ownership History from Q1 2015 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

Shares (Excl. Options)

9,481,572

Price

$3.00

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Ordinary Shares, nominal value EUR0.05 per share
Symbol: CLLS on Nasdaq
All holders as of 30 Jun 2026: Q2 2026
Total 13F shares: 9,481,572
Total 13F value: $28,445,409
Portfolio coverage rank: 0%
Share change: -773,631
Value change: -$2,350,285
Number of holders: 27
Shares outstanding: 95,490,450
SEC-reported price per share: $1.51

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Filing notes and source

Key facts

CLLS - Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share is tracked under CUSIP 15117K103.
27 institutions reported positions in Q2 2026.
3 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 32 to 27 between Q1 2026 and Q2 2026.
SEC-reported value moved from $32,488,978 to $28,445,409.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 27 institutions filings for Q2 2026.

Open SEC evidence

Security key

15117K103

13F reference period

Q2 2026

13F holders

13D/G owners

CIK / CUSIP context first

Open Q2 2026 holders CLLS full holder history Cellectis S.A. SEC filings Cellectis S.A. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 15117K103:

Q3 2026 (3 holders) Q2 2026 (27 holders) Q1 2026 (32 holders) Q4 2025 (34 holders) Q3 2025 (28 holders) Q2 2025 (24 holders) Q1 2025 (27 holders) Q4 2024 (29 holders) Q3 2024 (27 holders) Q2 2024 (27 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

CLLS

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
ASTRAZENECA PLC	44%		$66,440,000		44,000,000		AstraZeneca PLC	23 Jan 2025
Bpifrance Participations SA	11%	-15%	$33,176,247	+$960,243	10,599,440	+3%	Caisse des Depots	03 Dec 2025
Long Focus Capital Management, LLC	4.6%		$6,972,112		4,617,293		LONG FOCUS CAPITAL MANAGEMENT, LLC	31 Dec 2024

As of 30 Jun 2026, 27 institutional investors reported holding 9,481,572 shares of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS). This represents 9.9% of the company’s total 95,490,450 outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Headline period

Q2 2026

Rows shown

1-25 of 47

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2026 Q3	35,501	$53,606	+$51,461			$1.51	3
2026 Q2	9,481,572	$28,445,409	-$2,350,285			$3.00	27
2026 Q1	10,249,065	$32,488,978	-$1,008,296			$3.17	32
2025 Q4	10,548,060	$51,052,315	+$10,425,733		$0	$4.84	34
2025 Q3	8,311,195	$23,687,285	-$5,592,819		$150,195	$2.85	28
2025 Q2	11,757,728	$17,853,958	-$2,754,141			$1.52	24
2025 Q1	13,602,212	$16,864,343	-$51,496	$0	$0	$1.24	27
2024 Q4	12,759,251	$22,964,294	-$366,691	$3,060	$5,580	$1.80	29
2024 Q3	9,766,379	$20,863,531	-$17,239	$2,996	$12,626	$2.14	27
2024 Q2	9,772,625	$18,275,141	+$2,408,132	$33,473	$5,236	$1.87	27
2024 Q1	9,854,602	$26,115,627	+$90,284	$81,885	$0	$2.65	31
2023 Q4	9,816,725	$30,235,236	-$3,425,688	$4,312	$1,540	$3.08	33
2023 Q3	11,480,546	$18,138,183	-$4,873,642	$1,264	$4,740	$1.58	28
2023 Q2	14,008,673	$27,590,926	-$2,313,872	$2,167	$10,441	$1.97	31
2023 Q1	15,157,594	$29,256,650	+$12,430,028	$0	$0	$1.93	29
2022 Q4	8,733,333	$18,344,069	-$3,514,674	$3,150	$1,470	$2.10	37
2022 Q3	10,299,547	$23,616,856	-$1,469,623	$0		$2.29	43
2022 Q2	10,831,048	$30,655,602	-$4,582,029	$29,000	$0	$2.83	39
2022 Q1	12,267,940	$55,746,674	-$33,254,202	$203,000	$270,000	$4.54	45
2021 Q4	15,187,964	$123,726,723	-$17,963,859	$220,000	$302,000	$8.12	55
2021 Q3	15,388,771	$194,068,172	-$11,531,807	$408,000	$476,000	$12.61	65
2021 Q2	16,213,399	$250,623,262	+$15,081,703	$800,000	$437,000	$15.47	71
2021 Q1	15,242,452	$308,003,839	-$24,336,115	$1,562,000	$960,000	$20.21	78
2020 Q4	16,303,634	$441,619,228	+$62,320,026	$990,000	$2,322,000	$27.06	83
2020 Q3	14,221,535	$263,393,288	+$6,612,668		$374,000	$18.50	70